Hengbang Wang

733 total citations
30 papers, 350 citations indexed

About

Hengbang Wang is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Hengbang Wang has authored 30 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 14 papers in Oncology and 12 papers in Genetics. Recurrent topics in Hengbang Wang's work include Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Hengbang Wang is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Hengbang Wang collaborates with scholars based in China, United States and Australia. Hengbang Wang's co-authors include Yifan Zhai, Dajun Yang, Bo Wen, Duxin Sun, Guangfeng Wang, Donna McEachern, Xiaoqin Li, Liu Liu, Ming Guo and Ding Du and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Hengbang Wang

26 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hengbang Wang China	10	168	127	85	79	68	30	350
Harish Nagaraj Singapore	7	190 1.1×	134 1.1×	103 1.2×	74 0.9×	113 1.7×	8	365
Katalin Csermak Switzerland	5	157 0.9×	57 0.4×	21 0.2×	96 1.2×	72 1.1×	6	324
Christopher Weier United States	9	257 1.5×	81 0.6×	93 1.1×	105 1.3×	92 1.4×	13	530
Yung Kiang Loh Singapore	4	243 1.4×	152 1.2×	25 0.3×	118 1.5×	143 2.1×	7	389
Jonathan S. George United States	6	115 0.7×	154 1.2×	85 1.0×	78 1.0×	73 1.1×	7	471
Kwee Hyun Suh South Korea	9	141 0.8×	150 1.2×	69 0.8×	39 0.5×	78 1.1×	32	341
Stacey Shepard United States	6	100 0.6×	77 0.6×	111 1.3×	64 0.8×	90 1.3×	6	390
Andreas Floersheimer Switzerland	5	129 0.8×	86 0.7×	80 0.9×	111 1.4×	71 1.0×	7	304
Liv Johannessen United States	8	241 1.4×	152 1.2×	42 0.5×	24 0.3×	35 0.5×	19	374
John Waas United States	4	261 1.6×	193 1.5×	72 0.8×	109 1.4×	27 0.4×	6	487

Countries citing papers authored by Hengbang Wang

Since Specialization

Citations

This map shows the geographic impact of Hengbang Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hengbang Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hengbang Wang more than expected).

Fields of papers citing papers by Hengbang Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hengbang Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hengbang Wang. The network helps show where Hengbang Wang may publish in the future.

Co-authorship network of co-authors of Hengbang Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Hengbang Wang. A scholar is included among the top collaborators of Hengbang Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hengbang Wang. Hengbang Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qiu, Haibo, Zhiyan Liang, Jing Yang, et al.. (2025). Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. Signal Transduction and Targeted Therapy. 10(1). 361–361.

Li, Ning, Xing Zhang, Meiyu Fang, et al.. (2025). A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 6102–6102. 1 indexed citations

Lasica, Masa, Sikander Ailawadhi, Chengcheng Fu, et al.. (2024). Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 42(16_suppl). 7078–7078. 1 indexed citations

Qiu, Haibo, Zhiwei Zhou, Ye Zhou, et al.. (2024). Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.. Journal of Clinical Oncology. 42(16_suppl). 11502–11502. 9 indexed citations

Wang, Hengbang, et al.. (2024). Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers. Clinical and Translational Science. 17(9). e70021–e70021. 1 indexed citations

Yang, Yun, et al.. (2024). Abstract 3223: Embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and MDM2 inhibitor alrizomadlin (APG-115) synergistically inhibit tumor growth in preclinical models of prostate cancer (PCa). Cancer Research. 84(6_Supplement). 3223–3223. 1 indexed citations

Ailawadhi, Sikander, Asher Chanan‐Khan, Jack Khouri, et al.. (2024). Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis. Blood. 144(Supplement 1). 1022–1022.

Lakhani, Nehal J., Drew Rasco, Hengbang Wang, et al.. (2023). First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 30(3). 506–521. 13 indexed citations

Ailawadhi, Sikander, Masa Lasica, Chengcheng Fu, et al.. (2023). Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 41(16_suppl). 7569–7569.

10.

Qiu, Haibo, Zhiwei Zhou, Ye Zhou, et al.. (2023). Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 41(16_suppl). 11540–11540. 3 indexed citations

11.

Yu, Zhiheng, Xueting Yao, Hengbang Wang, et al.. (2022). Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models. Frontiers in Pharmacology. 13. 1065130–1065130. 4 indexed citations

12.

Zhao, Hongyun, Jianhua Chen, Zhengbo Song, et al.. (2022). First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1⁺ non–small cell lung cancer (NSCLC) or mesothelioma.. Journal of Clinical Oncology. 40(16_suppl). 9071–9071. 10 indexed citations

13.

Jiang, Qian, Ya‐Zhen Qin, Ting Zhao, et al.. (2021). Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML). Blood. 138(Supplement 1). 311–311. 10 indexed citations

14.

Rasco, Drew, Nehal J. Lakhani, Hengbang Wang, et al.. (2020). Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3508–3508. 6 indexed citations

15.

Lakhani, Nehal J., Drew Rasco, Qi Zeng, et al.. (2020). First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3509–3509. 17 indexed citations

16.

Tolcher, Anthony W., et al.. (2019). Abstract A086: Phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in U.S.. Molecular Cancer Therapeutics. 18(12_Supplement). A086–A086. 3 indexed citations

17.

Rasco, Drew, Nehal J. Lakhani, Yufeng Li, et al.. (2019). A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3126–3126. 22 indexed citations

18.

Xu, Rui‐Hua, Yuhong Li, Jiao Ji, et al.. (2018). A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2593–2593. 6 indexed citations

19.

Jiang, Qian, Xiao Jun Huang, Zi Chen, et al.. (2018). Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study. Blood. 132(Supplement 1). 791–791. 10 indexed citations

20.

Aguilar, Angelo, Jianfeng Lü, Liu Liu, et al.. (2017). Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. Journal of Medicinal Chemistry. 60(7). 2819–2839. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact